Stonegate Initiates Coverage on StimCell Energetics Inc. (STME)

Fri, 15 May 2026 12:22:00 -0400

Dallas, Texas--(Newsfile Corp. - May 15, 2026) - StimCell Energetics Inc. (OTCQB: STME): Stonegate Initiates Coverage on StimCell Energetics Inc. (OTCQB: STME). StimCell is a single-product company focused on eBalance®. Rather than managing a broad portfolio, the Company is centered on advancing one core platform. The current emphasis appears to be on redesigning eBalance into a compact consumer unit optimized for home use, and the Company's SEC filings state that StimCell is focused on the discovery, development, and commercialization of both therapeutic and non-therapeutic products that promote general wellness.

To view the full announcement, including downloadable images, bios, and more,

Stonegate Initiates Coverage on StimCell Energetics Inc. (STME)

Fri, 15 May 2026 12:22:00 -0400

To view the full announcement, including downloadable images, bios, and more,

Form 10-Q Stimcell Energetics Inc. For: Feb 28

Fri, 10 Apr 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20260410/26299718.html

Form 10-Q Stimcell Energetics Inc. For: Feb 28

Fri, 10 Apr 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20260410/26299718.html

Form 10-Q Stimcell Energetics Inc. For: Feb 28

Fri, 10 Apr 2026 15:41:00 -0400

si-local-file:///var/storage/secattach/20260410/26299718.html

StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach

Thu, 19 Mar 2026 09:15:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce that it has engaged Stonegate Capital Partners, Inc. ("Stonegate") to provide research coverage and institutional investor outreach services.

Pursuant to the Advisory Services Agreement effective March 12, 2026, Stonegate will deliver comprehensive services including quarterly updated research, ongoing investor relations consultation and representation and coordination of targeted institutional investor meetings.

As compensation for the initial twelve-month term, the Company will

StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach

Thu, 19 Mar 2026 09:15:00 -0400

VANCOUVER, BC / ACCESS Newswire / March 19, 2026 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce that it has engaged Stonegate Capital Partners, Inc. ("Stonegate") to provide research coverage and institutional investor outreach services.

As compensation for the initial twelve-month term, the Company will

StimCell Energetics Inc. Announces Study into eBalance(R) Device's Impact on Neuronal Mitochondrial Function

Tue, 02 Dec 2025 09:15:00 -0400

VANCOUVER, BC / ACCESS Newswire / December 2, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, today announced the signing of a service agreement with the St. Boniface Hospital Albrechtsen Research Centre, affiliated with the University of Manitoba, and Principal Investigator, Professor Paul Fernyhough. This collaboration will explore the effects of StimCell's proprietary eBalance® device on mitochondrial function in cultured sensory neurons to further define the physiological action of microcurrents.

Under the agreement, effective December 1, 2025, Dr. Fernyhough's

StimCell Energetics Inc. Announces Study into eBalance(R) Device's Impact on Neuronal Mitochondrial Function

Tue, 02 Dec 2025 09:15:00 -0400

Under the agreement, effective December 1, 2025, Dr. Fernyhough's

StimCell Energetics Inc. Successfully Uplists to OTCQB Market

Fri, 24 Oct 2025 15:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / October 24, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech pioneer targeting cellular energy to enhance wellness, anti-aging, and longevity, is pleased to announce its successful uplisting to the OTCQB Venture Market, effective October 24, 2025. This significant milestone reflects the company's commitment to enhancing transparency, improving liquidity, and expanding its visibility within the investment community.

The OTCQB, operated by OTC Markets Group, is a premier marketplace for early-stage and developing companies that meet high standards of financial reporting and corporate governance. By

StimCell Energetics Inc. Successfully Uplists to OTCQB Market

Fri, 24 Oct 2025 15:00:00 -0400

The OTCQB, operated by OTC Markets Group, is a premier marketplace for early-stage and developing companies that meet high standards of financial reporting and corporate governance. By

BofA sees rising China risk for EU tech firms as domestic shift deepens

Wed, 21 May 2025 07:42:05 -0400

Investing.com -- European tech companies face mounting risks from China’s accelerating push for self-sufficiency, according to a new note from Bank of America on Wednesday.

With China accounting for 29% of global semiconductor sales in 2024, Beijing’s “Made in China 2025” policy poses growing challenges for European IT hardware players, according to BofA.

“We analyse the risk of a complete decoupling from China,” BofA analysts wrote, warning that European companies with significant exposure to China could face sharp earnings and valuation pressures.